2 Dividend Stocks to Buy Hand Over Fist in November was originally published by The Motley Fool Their recent issues are ...

Dividend stocks are attractive for their steady income, stability, and growth potential, especially amid low interest rates ...

As most advisors are well aware, high stock prices have pushed down the market’s dividend yield. Barron’s ran a screen for ...

One of the best ways to build wealth is with dividend stocks – especially if they’re attached to solid companies with a ...

Morgan Stanley lowered the firm’s price target on AbbVie (ABBV) to $224 from $231 and keeps an Overweight rating on the shares following ...

Discover how AbbVie investors that bought the anxiety over the loss of Humira exclusivity are sitting on massive gains. Read ...

Cerevel wasn't a one-trick pony, however. For its considerable spend, AbbVie also acquired several other pipeline programs from the neuroscience-focused biotech. The most promising of these is ...

Dividend yield and robust drug pipeline are bullish ... Data by YCharts Shares of AbbVie experienced one of their worst ...

AbbVie shares, which hit a 52-week high in late October after the drugmaker posted quarterly earnings that topped Wall Street's expectations and raised its dividend by nearly 6%, were recently down ...

In trading on Monday, shares of AbbVie crossed below their 200 day moving average of $178.81, changing hands as low as $172.70 per share.

Strategists at Wells Fargo Investment Institute see the fed funds rate dropping a total of one percentage point this year and ...